Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
CH0106213793
Tue, 18.07.2023
Spexis AG
First Berlin Equity Research has published a research update on Spexis AG
(ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating
and maintained his CHF 1.80 price target.
Abstract:
Spexis AG reported FY/22 results which, adjusted for non-cash goodwill
impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Tue, 18.07.2023
Spexis AG
First Berlin Equity Research has published a research update on Spexis AG
(ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating
and maintained his CHF 1.80 price target.
Abstract:
Spexis AG reported FY/22 results which, adjusted for non-cash goodwill
impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Wed, 25.01.2023
Spexis AG
First Berlin Equity Research has initiated coverage on Spexis AG (ISIN:
CH0106213793). Analyst Christian Orquera's rating is BUY with a price
target of CHF 1.80.
Abstract:
Spexis AG is a biotech company with a clinical-stage product pipeline
focused on rare diseases and oncology. Spexis is the result of the merger
of the rare diseases specialist [ … ]